PMA device
Healon EndoCoat Ophthalmic Viscosurgical Device (OVD) (3% Sodium Hyaluronate)
Johnson & Johnson Surgical Vision, Inc. · Aid, Surgical, Viscoelastic (LZP, Class III) · First FDA decision Oct 31, 2017, newest Apr 15, 2024Cataract
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
2
PMA pathway
Device trials
3
Naming "Healon EndoCoat Ophthalmic"
MAUDE reports
0
Brand "Healon EndoCoat Ophthalmic", since 2015
PubMed studies
0
Mentioning "Healon EndoCoat Ophthalmic"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Healon EndoCoat Ophthalmic Viscosurgical Device (OVD) (3% Sodium Hyaluronate)
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 0 of 2 decisions filed under this name.
FDA's records could not be loaded.
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Healon EndoCoat Ophthalmic", any status and sponsor, newest update first.
- Clinical Investigation of Healon EndoCoat Ophthalmic Viscosurgical Device (OVD)Pivotal-lookingCompleted
Johnson & Johnson Surgical Vision, Inc.Not on our public-company list
NCT05575063 · 165 participants · Start Nov 8, 2022 · Primary completion Dec 21, 2023
Device: Investigational Healon Endocoat; Control Healon EndoCoat · For: Cataracts
Sites: Bakersfield, California; Long Beach, California; Cranberry Township, Pennsylvania · 8 sites in all
- Study to Evaluate the Safety of the Viscoelastic Substance PRO-149, Compared to Healon® EndoCoat.Completed
Laboratorios Sophia S.A de C.V.Not on our public-company list
NCT04702802 · 36 participants · Start Sep 7, 2021 · Primary completion Oct 29, 2021
Device: Sodium hyaluronate 3%; Sodium hyaluronate 3% · For: Age-related Cataract; Phacoemulsification
Sites: Mexico City, Mexico
- Comparison of the Safety and Efficacy of Ophtesis Bio 3% With a Similar 3% Sodium Hyaluronate OVDStatus unknown
Gemini Eye ClinicNot on our public-company list
NCT05832749 · 296 participants (planned) · Start Aug 23, 2022 · Primary completion Apr 2023
Device: Ophtesis Bio 3% ophthalmic viscosurgical device; Healon Endocoat 3% ophthalmic viscosurgical device · For: Bilateral Cataract; Unilateral Cataract
Sites: Průhonice, Czechia; Vyškov, Czechia; Zlín, Czechia
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Healon EndoCoat Ophthalmic", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code LZP
0 reports: 0 malfunction, 0 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Healon EndoCoat Ophthalmic"[tiab]. The summary above synthesizes these.
No PubMed record mentions this device by name.
Other devices of this type
Also filed under product code LZP.
- PROVISC Ophthalmic Viscosurgical DeviceAlcon Research, Ltd. · PMA 2026
- Sodium Hyaluronate Ophthalmic Viscoelastic Devices (OVD)Johnson & Johnson Surgical Vision, Inc. · PMA 2024
- Amvisc & Amvisc Plus OvdBausch & Lomb, Inc. · PMA 2017
- Staarvisc II & Shellgel Sodium HyauronateAnika Therapeutics, Inc. · PMA 2012
- VISCOAT Ophthalmic Viscosurgical DeviceAlcon Laboratories · PMA 2026
- DISCOVISC Ophthalmic Viscosurgical DeviceAlcon Laboratories · PMA 2021
- Cellugel(R) Ophthalmic Viscosurgical DeviceAlcon Laboratories · PMA 2016
- Ocucoat (2% Hydroxpropylmethylcellulose Solution)Bausch & Lomb, Inc. · PMA 2012
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.